Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    "Papillary renal cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
Condition: Papillary Renal Cell Carcinoma
Intervention: Drug: axitinib
2 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin
3 Active, not recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Tivantinib
4 Recruiting Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate;   Drug: Volitinib
5 Active, not recruiting Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
6 Active, not recruiting Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Renal Cell Carcinoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Renal Cell Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
7 Active, not recruiting Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Conditions: Adult Acute Myeloid Leukemia in Remission;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndrome;   Childhood Renal Cell Carcinoma;   Chronic Myelomonocytic Leukemia;   Clear Cell Renal Cell Carcinoma;   de Novo Myelodysplastic Syndrome;   Metastatic Renal Cell Cancer;   Previously Treated Myelodysplastic Syndrome;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Renal Medullary Carcinoma;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Fludarabine Phosphate;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
8 Active, not recruiting Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   B-cell Chronic Lymphocytic Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Childhood Renal Cell Carcinoma;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Waldenström Macroglobulinemia
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Completed A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Condition: Carcinoma, Renal Cell
Intervention: Drug: foretinib (formerly GSK1363089 or XL880)
10 Recruiting CREATE: Cross-tumoral Phase 2 With Crizotinib
Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma;   Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor;   Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1;   Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma;   Locally Advanced and/or Metastatic Clear Cell Sarcoma;   Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)
11 Recruiting A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Clear-cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Kidney Diseases;   Kidney Neoplasms;   Metastatic Renal Cell Carcinoma
Intervention: Drug: CDX-014
12 Recruiting A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Condition: Papillary Renal Cell Carcinoma
Intervention: Drug: INC280
13 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Carcinoma of the Collecting Ducts of Bellini;   Chromophobe Renal Cell Carcinoma;   Kidney Medullary Carcinoma;   Kidney Oncocytoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Intervention: Drug: Pazopanib Hydrochloride
14 Completed Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Conditions: Childhood Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Clear Cell Sarcoma of the Kidney;   Papillary Renal Cell Carcinoma;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Renal Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Renal Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Renal Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Renal Wilms Tumor
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Irinotecan Hydrochloride;   Procedure: Conventional Surgery;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Dactinomycin;   Drug: Vincristine Sulfate;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis
15 Completed
Has Results
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Conditions: Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Biological: Bevacizumab;   Drug: Sorafenib Tosylate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
16 Terminated Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Biological: recombinant interferon alfa;   Other: laboratory biomarker analysis
17 Active, not recruiting A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Condition: Papillary Renal Cell Cancer
Intervention: Drug: AZD6094
18 Unknown  Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Condition: Kidney Cancer
Intervention: Drug: sunitinib malate
19 Terminated
Has Results
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Condition: Kidney Cancer
Intervention: Biological: bevacizumab
20 Recruiting Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
Condition: Prostate Cancer
Intervention: Biological: Cancer Macrobead placement in abdominal cavity

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Indicates status has not been verified in more than two years